glp-1 retatrutide Doctor’s WARNING: The Dark Side of Weight Loss (Is WORSE Than Tirzepatide?) Retatrutide Weight Loss Results:Trial Data

not yet approved Tirzepatide : FDA-approved as Mounjaro (2022) for T2D and Zepbound (2023) for obesity Advantage : Tirzepatide Side Effect Profile# Retatrutide : GI side effects common

But what about the third group

The average HbA1c reduction may have been attenuated by floor effect, as a high proportion of participants approached near-normal glycaemic levels

They can also reduce levels of hormones like testosterone in the blood, which can relieve common PMOS symptoms such as excess hair growth or acne

After a median follow-up of 3.2 years (duration of drug exposure 2.4 years) the primary outcome was reduced in the exenatide treated group, but this difference just missed achieving statistical significance (HR 0.91